Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) COO Sells $654,807.42 in Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $152.21, for a total transaction of $654,807.42. Following the completion of the transaction, the chief operating officer owned 2,154 shares of the company’s stock, valued at approximately $327,860.34. The trade was a 66.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kathleen Goin also recently made the following trade(s):

• On Wednesday, June 17th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The shares were sold at an average price of $110.73, for a total transaction of $476,360.46.

Palvella Therapeutics Price Performance

Shares of NASDAQ:PVLA opened at $142.04 on Friday. The company’s fifty day moving average price is $142.35 and its 200 day moving average price is $124.46. Palvella Therapeutics, Inc. has a 12 month low of $49.13 and a 12 month high of $161.38. The firm has a market capitalization of $2.05 billion, a P/E ratio of -29.41 and a beta of -0.17.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). On average, sell-side analysts anticipate that Palvella Therapeutics, Inc. will post -6.36 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Truist Financial set a $207.00 price target on Palvella Therapeutics in a research note on Wednesday, August 5th. Canaccord Genuity Group set a $232.00 price target on Palvella Therapeutics in a research report on Wednesday, August 5th. Chardan Capital upgraded Palvella Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Finally, Stephens reissued an “overweight” rating and issued a $220.00 price objective on shares of Palvella Therapeutics in a report on Thursday, May 21st. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $209.14.

Institutional Trading of Palvella Therapeutics

Several hedge funds have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Palvella Therapeutics in the second quarter valued at approximately $35,000. Penn Capital Management Company LLC purchased a new position in Palvella Therapeutics in the second quarter worth $841,000. Hsbc Holdings PLC purchased a new position in Palvella Therapeutics in the second quarter worth $7,641,000. Wellington Management Group LLP lifted its holdings in Palvella Therapeutics by 4.6% in the second quarter. Wellington Management Group LLP now owns 35,594 shares of the company’s stock valued at $5,439,000 after acquiring an additional 1,554 shares during the period. Finally, Archer Investment Corp acquired a new stake in Palvella Therapeutics in the second quarter valued at $69,000. 40.11% of the stock is owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.